secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anixa Biosciences Inc (ANIX)
CIK:        0000715446
Form:       8-K
Filed at:   2025-12-12T23:59:59+00:00
Accession:  0001493152-25-027321
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anixa reports final Phase 1 breast cancer vaccine data: 74% immune response, safe, advancing to Phase 2
--------------------------------------------------------------------------------

- Vaccine met all primary endpoints; 74% of participants showed protocol-defined aLA-specific T cell responses.
- Well tolerated at max tolerated dose; main adverse event was injection-site irritation; no flu-like symptoms.
- Combination with Keytruda generated T cell responses without major additional side effects.
- Enrolled 35 participants across three cohorts: early-stage TNBC, preventive mastectomy, adjuvant Keytruda.
- Planning Phase 2 neoadjuvant combination study with Keytruda in newly diagnosed breast cancer patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/715446/000149315225027321/0001493152-25-027321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/715446/000149315225027321/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-027321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer